Marvin Herzberger
Marvin Herzberger is a publishing trader at TraderFox GmbH and group leader for the technical analysis of the DAX. He has been actively engaged in technical analysis since 2011. In this context, he has tested, analyzed, and evaluated various trading strategies in practical implementation. His area of expertise lies in swing trading. The analyses cover a short-term time horizon of up to 10 days.
Latest from Marvin Herzberger
Salesforce: US Department of Commerce Opens Doors for Global AI Export!
The US Department of Commerce includes Salesforce in its export program for future technologies. ...
Modexus Solutions Inc.: Oppenheimer's price target of $240 meets hesitant markets
Modexus aims to achieve significant revenue growth in the data center sector by the fiscal year 2029...
Unusual Machines: Strategic Positioning in the NDAA-Compliant Drone Components Market - Oppenheimer Sees Potential for Tripling Stock Price!
Why a supplier benefits from the US military's drone programs regardless of the final platform winner....
AT&S: Ramp-Up of Facilities in Asia Shapes Current Quarterly Margins
The business model of AT&S focuses on IC substrates and benefits from trends such as Advanced Packaging....
Hornbach Holding: Market Share Gains in Challenging Times - I Expect a Breakout to a New 52-Week High!
The current overall market environment is challenging, and consumer sentiment in Europe is not exactly...
Carvana: Expansion of Same-Day Delivery in Massachusetts as a Lever for Further Scaling!
Carvana grows with a sales increase of 39% in a stagnant market environment. The expansion of same-day...
TJX Companies Inc.: Off-Price Model Ensures Double-Digit Margins Despite Warm Weather - Stock Price Surges Over 5%!
Revenue rose in the 3rd quarter of the fiscal year 2027 to $16.0 billion. Same-store sales grew by...
SELLAS Life Sciences: Phase 3 Success for Cancer Vaccine GPS Drives Price Target to $40 by Maxim!
The cancer vaccine GPS from SELLAS Life Sciences (SLS) achieved an extension of overall survival in...
Forgent Power Solutions: Insider Purchases and Forecast Boost - Is the Current Turmoil an Attractive Entry Opportunity?
With a view to the recovery of AI beneficiaries, selection is becoming more pronounced once again. One...
Microchip Technology Inc.: New Ethernet Switches Propel the Era of Software-Defined Vehicles!
MCHP focuses on system solutions for industrial and automotive customers. The LAN9324x and LAN9322x...
Astera Labs: Network Specialist Positions Itself in the Shadow of AI Giants - Hyve Deal Boosts Stock After Price Drop
AI connectivity specialist expands market position in cloud infrastructure. Extended collaboration...
Rezolute: Wedbush Raises Price Target After upLIFT Study Data - Experts See 173% Price Potential!
Wedbush sets a price target for Rezolute (RZLT) at 10 USD after positive Phase 3 data for Ersodetug....
Adesso: 26% EBITDA Growth and the Strategic Shift to the Agentic Enterprise
The IT service provider Adesso (i.) has recorded a significant increase in operational earnings in the...
Friedrich Vorwerk: Margin Surge and US Expansion in Focus of Energy Infrastructure
The business model of Friedrich Vorwerk is focused on the planning and implementation of energy infrastructure...
Vusion: Cyber Threats at the Cooling Shelf Could Make Vusion an Indispensable Security Partner for Retail!
The recent wave of cyberattacks on supermarket cooling systems in Europe is a wake-up call for the industry...
CG Oncology: Late-stage study paves the way for early bladder cancer therapy - With a 30% stock increase to a new all-time high!
Novel therapy using special viruses to combat cancer cells offers urgently needed treatment options...
Humana: RBC Raises Price Target, Highlighting Profit Potential Until 2028!
Strategy focus on profitable Medicare customers drove revenue to 41.2 billion USD recently. The RBC...
Rocket Pharmaceuticals: How Danon Studies Drive Valuation Levels - Experts See Up to 422% Price Potential!
Focus on AAV-based gene therapies for rare diseases, with Danon disease as the primary pipeline driver....
Dexcom: Innovation and Services as Drivers of Returns - I Expect a Breakout to a New 52-Week High Soon!
Today, Dexcom (DXCM) caught my attention with compelling fundamentals. The company increased its revenue...
Regeneron: Billion-Dollar Deal with Sanofi and New Approvals Secure Market Position
Revenue climbed in the third quarter to $5.1 billion, driven by sales figures for Dupixent and Eylea...